

GLAXOSMITHKLINE PLC  
Form 6-K  
February 01, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending February 2016

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons

In accordance with DTR 3.1.4R(1)(a) and (c) I give details of changes in the interests of the following Directors and Persons Discharging Managerial Responsibilities ('PDMR') who acquired Ordinary Shares ('Shares') in GlaxoSmithKline plc ('GSK') at a price of 1367.57 pence per Share, following the re-investment of the dividend paid to shareholders on 14 January 2016.

Director/PDMR	Shares
Sir Andrew Witty	28.610
Mr S Dingemans	937.309
Mr S A Hussain	30.863
Mr D S Redfern	813.543
Dr M M Slaoui	164.460
Ms C Thomas	998.661
Mr P C Thomson	341.837
Dr P J T Vallance	1,210.723
Ms E Walmsley	939.015

Connected Person	Shares
Mrs K Thomson (Connected Person to Mr P C Thomson)	110.075

GSK was informed of these allocations on 28 January 2016.

V A Whyte  
Company Secretary

1 February 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 01, 2016

By: VICTORIA WHYTE  
-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc